Ignite Creation Date:
2024-05-06 @ 7:00 PM
Last Modification Date:
2024-10-26 @ 2:59 PM
Study NCT ID:
NCT05864742
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-05-10
First Post:
2023-05-01
Brief Title:
Genetically Risk-Stratified Venetoclax Ibrutinib Rituximab Navitoclax in RelapsedRefractory Mantle Cell Lymphoma
Sponsor:
Peter MacCallum Cancer Centre Australia
Organization:
Peter MacCallum Cancer Centre Australia
Key Dates - Follows AllAPIJSON File Order
Start Date:
2023-09-07
Start Date Type:
ACTUAL
Primary Completion Date:
2026-06-01
Primary Completion Date Type:
ESTIMATED
Completion Date:
2029-06-01
Completion Date Type:
ESTIMATED
First Submit Date:
2023-05-01
First Submit QC Date:
May 16 2023
Study First Post Date:
2023-05-18
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-08-08
Last Update Post Date:
2024-05-10
Last Update Post Date Type:
ACTUAL